BioSpace News Archive

Medifocus, Inc. announced its decision to terminate and suspend the registration of its stock with the Securities and Exchange Commission.

Vor Bio, a clinical-stage cell and genome engineering company, reported financial results for the three-month period ended March 31, 2022, and provided a business update.

CooperCompanies, will participate in the Jefferies Healthcare Conference on Thursday, June 9, 2022.

23andMe Holding Co., a leading consumer genetics and research company, announced that it will report financial results for the fiscal year 2022 fourth quarter and full year after the market closes on Thursday, May 26, 2022.

Cingulate Inc. announced its financial results for the three months ended March 31, 2022, and provided a clinical and business update, which includes the announcement of first subject dosing in its human formulation study of CTx-2103 for the treatment of anxiety.

AVITA Medical, Inc. reported financial results for its first quarter ended March 31, 2022.

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today provided a corporate update and reported financial results for the first quarter ended March 31, 2022.

Graphite Bio, Inc. reported recent business progress and first quarter 2022 financial results.

Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or quality of life, today announced financial results for the quarter ended March 31, 2022, and provided an update on its clinical programs.

Astria Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.